Patent application number | Description | Published |
20140057938 | KAT ll INHIBITORS - Compounds of Formula I: | 02-27-2014 |
20140128374 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 05-08-2014 |
20140336176 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 11-13-2014 |
20150175573 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 06-25-2015 |
20150175603 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS - Compounds of Formula (I), wherein R | 06-25-2015 |
20150196561 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 07-16-2015 |
20150291625 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands - The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses. | 10-15-2015 |